Difference between revisions of "Fludarabine (Fludara)"
Jump to navigation
Jump to search
m |
m |
||
| Line 2: | Line 2: | ||
Class/mechanism: Purine analog, antimetabolite; fludarabine is converted to the active compound, 2-fluoro-ara-ATP, which inhibits DNA synthesis by inhibiting DNA polymerase alpha, ribonucleotide reductase, and DNA primase. Relatively resistant to deamination by adenosine deaminase. The mechanism of action is not completely characterized and may be multi-faceted.<ref name="insert">[http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4067b1_15_fludarabine%20label.pdf Fludarabine (Fludara) package insert]</ref><ref>[[Media:Fludarabine.pdf | Fludarabine (Fludara) package insert (locally hosted backup)]]</ref> | Class/mechanism: Purine analog, antimetabolite; fludarabine is converted to the active compound, 2-fluoro-ara-ATP, which inhibits DNA synthesis by inhibiting DNA polymerase alpha, ribonucleotide reductase, and DNA primase. Relatively resistant to deamination by adenosine deaminase. The mechanism of action is not completely characterized and may be multi-faceted.<ref name="insert">[http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4067b1_15_fludarabine%20label.pdf Fludarabine (Fludara) package insert]</ref><ref>[[Media:Fludarabine.pdf | Fludarabine (Fludara) package insert (locally hosted backup)]]</ref> | ||
<br>Route: IV ''Note: Oral fludarabine is no longer available, at this time.'' | <br>Route: IV ''Note: Oral fludarabine is no longer available, at this time.'' | ||
| − | <br>Extravasation: | + | <br>Extravasation: [[neutral]] |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| Line 33: | Line 33: | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
[[Category:Intravenous chemotherapy]] | [[Category:Intravenous chemotherapy]] | ||
| + | [[Category:Neutral chemotherapy]] | ||
[[Category:DNA synthesis inhibitors]] | [[Category:DNA synthesis inhibitors]] | ||
Revision as of 20:44, 23 April 2017
General information
Class/mechanism: Purine analog, antimetabolite; fludarabine is converted to the active compound, 2-fluoro-ara-ATP, which inhibits DNA synthesis by inhibiting DNA polymerase alpha, ribonucleotide reductase, and DNA primase. Relatively resistant to deamination by adenosine deaminase. The mechanism of action is not completely characterized and may be multi-faceted.[1][2]
Route: IV Note: Oral fludarabine is no longer available, at this time.
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Aggressive Non-Hodgkin lymphoma
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Cold agglutinin disease
- Follicular lymphoma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Transplant conditioning regimens
- Waldenström macroglobulinemia
Patient drug information
- Fludarabine (Fludara) patient drug information (Chemocare)[3]
- Fludarabine (Fludara) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 4/18/1991: Initial FDA approval for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen.
Also known as
Beneflur, FAMP, Fludarabine Phosphate, Fludara Lyophilisat, Oforta, Trav Fludarabine.
References
Categories:
- Drug index
- Chemotherapy
- Intravenous chemotherapy
- Neutral chemotherapy
- DNA synthesis inhibitors
- Antimetabolites
- Purine analogues
- Acute myeloid leukemia medications
- Aggressive Non-Hodgkin lymphoma medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Cold agglutinin disease medications
- Follicular lymphoma medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Transplant medications
- Waldenström macroglobulinemia medications
- Drugs FDA approved in 1991
- WHO Essential Cancer Medicine